The "normal" Factor VIII Concentration in Plasma

Overview

Journal Thromb Res

Date 2010 May 11

PMID 20451961

Citations 8

Authors

Saulius Butenas

Behnaz Parhami-Seren

Anetta Undas

David N Fass

Kenneth G Mann

Affiliations

Soon will be listed here.

Abstract

Introduction: The quantitation of factor (F)VIII by activity-based assays is influenced by the method, procedure, the quality and properties of reagents used and concentrations of other plasma proteins, including von Willebrand factor (VWF).

Objective: To compare FVIII concentrations measured by activity-based assays with those obtained by an immunoassay and to establish the influence of plasma dilution on the FVIII clotting activity (FVIIIc).

Methods: The APTT, a chromogenic assay (Coatest) and two in-house immunoassays were used. Albumin-free recombinant FVIII was used as the calibrator in all assays.

Results: For a group of 44 healthy individuals (HI), the mean value observed for FVIII antigen (FVIIIag; 1.22+/-0.56 nM; S.D.) is substantially higher than that for FVIIIc (0.65+/-0.29 nM) and the chromogenic assay (FVIIIch; 0.50+/-0.23 nM). A positive correlation between FVIIIag and VWFag with R(2)=0.20 was observed. Since plasma VWF has an inhibitory effect on FVIIIc, we evaluated the influence of plasma dilutions on FVIIIc in HI (n=105). At a 4-fold dilution, estimates of FVIIIc by clotting assay were much lower than FVIIIag (0.77+/-0.31 vs. 1.14+/-0.48 nM). At 10- and 25-fold dilutions, the estimated FVIIIc increased to 0.87+/-0.36 and 0.94+/-0.44 nM, respectively.

Conclusions: 1) In plasma, FVIIIag is higher than FVIIIc and FVIIIch; and 2) Real FVIII concentrations in plasma can be estimated by measuring FVIIIag.

Citing Articles

Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.

Sarafanov A Int J Mol Sci. 2023; 24(10).

PMID: 37239930 PMC: 10217895. DOI: 10.3390/ijms24108584.

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report.

Albattat S, Alabdultaif A, Albattat F, Albattat B J Med Case Rep. 2023; 17(1):63.

PMID: 36814352 PMC: 9948523. DOI: 10.1186/s13256-023-03783-7.

Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies.

Root-Bernstein R, Huber J, Ziehl A Int J Mol Sci. 2022; 23(19).

PMID: 36232795 PMC: 9569991. DOI: 10.3390/ijms231911500.

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts.

Chun H, Kurasawa J, Olivares P, Marakasova E, Shestopal S, Hassink G J Thromb Haemost. 2022; 20(10):2255-2269.

PMID: 35810466 PMC: 9804390. DOI: 10.1111/jth.15817.

Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Bezaire J, Thomson D, McNair E J Extra Corpor Technol. 2018; 50(3):170-177.

PMID: 30250344 PMC: 6146271.

References

Lollar P, Knutson G, Fass D . Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid. Blood. 1984; 63(6):1303-8. View

de Visser M, Sandkuijl L, Lensen R, Vos H, Rosendaal F, Bertina R . Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost. 2003; 1(8):1771-6. DOI: 10.1046/j.1538-7836.2003.00314.x. View

Tuddenham E, Lane R, Rotblat F, Johnson A, Snape T, Middleton S . Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982; 52(2):259-67. DOI: 10.1111/j.1365-2141.1982.tb03888.x. View

Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedins K, Gomperts E, Rivard G . Quantitation of anti-factor VIII antibodies in human plasma. Blood. 2009; 113(11):2587-94. PMC: 2656278. DOI: 10.1182/blood-2008-08-174987. View

Souto J, Almasy L, Muniz-Diaz E, Soria J, Borrell M, Bayen L . Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000; 20(8):2024-8. DOI: 10.1161/01.atv.20.8.2024. View

ODonnell J, Mumford A, Manning R, Laffan M . Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000; 83(1):10-3. View

Muntean W, Hathaway W, Montgomery R . Influence of high molecular weight factor VIII on the measurement of low molecular weight factor VIII procoagulant in different assay systems. Br J Haematol. 1982; 51(4):649-58. DOI: 10.1111/j.1365-2141.1982.tb02829.x. View

Raut S, Sands D, Heath A, Barrowcliffe T . Variability in factor VIII concentrate measurement: results from SSC field collaborative studies. J Thromb Haemost. 2003; 1(9):1927-34. DOI: 10.1046/j.1538-7836.2003.00342.x. View

HOYER L . The factor VIII complex: structure and function. Blood. 1981; 58(1):1-13. View

10.

Hamer R, Koedam J, Bertina R, van Mourik J, Sixma J . Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem. 1987; 166(1):37-43. DOI: 10.1111/j.1432-1033.1987.tb13480.x. View

11.

Fass D, BOWIE E, OWEN Jr C, Mann K . Stability of porcine factor VIII. Thromb Res. 1975; 6(2):109-18. DOI: 10.1016/0049-3848(75)90016-x. View

12.

Cinotti S, Longo G, Messori A, Morfini M, Blomback M, Schimpf K . Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. Thromb Res. 1991; 61(4):385-93. DOI: 10.1016/0049-3848(91)90652-d. View

13.

Barrowcliffe T, Raut S, Sands D, Hubbard A . Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost. 2002; 28(3):247-56. DOI: 10.1055/s-2002-32658. View

14.

Chandler W, Ferrell C, Lee J, Tun T, Kha H . Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003; 120(1):34-9. DOI: 10.1309/C8T8-YNB4-G3W4-5PRF. View

15.

Ingerslev J, Jankowski M, Weston S, Charles L . Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost. 2004; 2(4):623-8. DOI: 10.1111/j.1538-7836.2004.00657.x. View

16.

Vidal F, Farssac E, Altisent C, Puig L, Gallardo D . Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001; 85(4):580-3. View

17.

Rodgers S, Duncan E, Barbulescu D, Quinn D, Lloyd J . In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol. 2007; 136(1):138-45. DOI: 10.1111/j.1365-2141.2006.06402.x. View

18.

Lollar P, Hill-Eubanks D, Parker C . Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988; 263(21):10451-5. View

19.

Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci P . A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost. 2003; 1(11):2283-9. DOI: 10.1046/j.1538-7836.2003.00481.x. View

20.

Lollar P, Fay P, Fass D . Factor VIII and factor VIIIa. Methods Enzymol. 1993; 222:128-43. DOI: 10.1016/0076-6879(93)22010-d. View